Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 25 of 250 entries
View as:

A Study of VRD-based Regimen Combined With CART-ASCT-CART2 Treatment in Patients With Primary Plasma Cell Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT05870917 Org: User:
Start: 04/25/23 End: 04/30/27 Due: 04/30/28

Optimal Timing of Hepatitis B Vaccination After Transplants

Phase: N/A Priority: Normal
NCT ID: NCT06888479 Org: User:
Start: 06/01/25 End: 03/01/29 Due: 03/01/30

Humanized Anti-CD25 Antibody for Prophylaxis of aGVHD in Elderly Underwent HID-HSCT

Phase: N/A Priority: Normal
NCT ID: NCT05923814 Org: User:
Start: 07/07/23 End: 05/07/24 Due: 05/07/25

CAR-T for Autoimmune Hemolytic Anemia Patients Who Have Failed Three or More Lines of Therapy

Phase: N/A Priority: Normal
NCT ID: NCT06212154 Org: User:
Start: 01/20/24 End: 06/30/25 Due: 06/30/26

Avatrombopag in the Treatment of Pediatric Immune Thrombocytopenia

Phase: N/A Priority: Normal
NCT ID: NCT06281327 Org: User:
Start: 03/01/24 End: 12/31/25 Due: 12/31/26

The Application of Ursodeoxycholic Acid for the Prevention of SARS-CoV-2 Infection (COVID-19)

Phase: N/A Priority: Normal
NCT ID: NCT05659654 Org: User:
Start: 12/16/22 End: 03/08/23 Due: 03/08/24

CD7 CAR-T for Patients With r/r CD7+ Hematologic Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT05454241 Org: User:
Start: 09/07/22 End: 08/31/24 Due: 08/31/25

A Clinical Study of CAR-T Cells in the Treatment of Relapsed and Refractory Hematological Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT04008524 Org: User:
Start: - End: - Due: -

Letermovir for Primary Prophylaxis of Cytomegalovirus Infection After R+HID-HSCT

Phase: N/A Priority: Normal
NCT ID: NCT05914675 Org: User:
Start: 07/01/23 End: 12/31/24 Due: 12/31/25

Gene Therapy for Hemophilia B Patients Aged 12-18 Years Old

Phase: N/A Priority: Normal
NCT ID: NCT05709288 Org: User:
Start: 03/23/23 End: 11/30/35 Due: 11/30/36

Study of Human Umbilical Cord-derived Mesenchymal Stem Cells for Treatment of Refractory Immune Thrombocytopenia

Phase: N/A Priority: Normal
NCT ID: NCT04014166 Org: User:
Start: 11/21/19 End: 06/30/23 Due: 06/30/24

A Randomized, Double-blind, Placebo-controlled, and Multi-center Clinical Study of CM313 in the Treatment of Immune Thrombocytopenia

Phase: N/A Priority: Normal
NCT ID: NCT06199089 Org: User:
Start: 01/16/24 End: 12/31/24 Due: 12/31/25

Combination of Inaticabtagene Autoleucel With Autologous Hematopoietic Stem Cell Transplantation for Adolescents or Adults With MRD-Positive B-Cell Acute Lymphoblastic Leukemia in Initial Complete Remission.

Phase: N/A Priority: Normal
NCT ID: NCT06608732 Org: User:
Start: 08/01/24 End: 07/01/28 Due: 07/01/29

CAR T-cell Therapy Targeting CD19 and BCMA in Patients With Relapse/Refractory Autoimmune Diseases

Phase: N/A Priority: Normal
NCT ID: NCT06941129 Org: User:
Start: 02/11/25 End: 03/18/28 Due: 03/18/29

A Study of VRd-based Regimen Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With New-diagnosed Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT05860036 Org: User:
Start: 04/01/23 End: 03/10/28 Due: 03/10/29

CD19 CAR-T in the Treatment of Relapsed/Refractory Autoimmune Diseases

Phase: N/A Priority: Normal
NCT ID: NCT06680388 Org: User:
Start: 11/15/24 End: 03/15/27 Due: 03/15/28

An Epidemiological Study to Investigate the Characteristics of RSV Infection in Adult Hematopoietic Cell Transplant Recipients or Hematological Malignancies Patients in Tianjin HI (Hematology Institute)

Phase: N/A Priority: Normal
NCT ID: NCT06490549 Org: User:
Start: 11/30/23 End: 06/20/25 Due: 06/20/26

Evaluation of Immune Status Before and After Splenectomy in Immune Thrombocytopenia Patients

Phase: N/A Priority: Normal
NCT ID: NCT03998059 Org: User:
Start: 01/23/19 End: 07/23/25 Due: 07/23/26

A Prospective, One-arm and Open Clinical Study of Obinutuzumab in the Treatment of Immune Thrombocytopenia

Phase: N/A Priority: Normal
NCT ID: NCT05995054 Org: User:
Start: 08/28/23 End: 08/31/26 Due: 08/31/27

Combination of Steroid and Humanized CD25 Monoclonal Antibody as First-line Therapy for aGVHD

Phase: N/A Priority: Normal
NCT ID: NCT06473909 Org: User:
Start: 07/01/24 End: 12/31/25 Due: 12/31/26

Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol

Phase: N/A Priority: Normal
NCT ID: NCT06764238 Org: User:
Start: 01/03/25 End: 06/30/31 Due: 06/30/32

DLCL002 Protocol for Patients With High Risk Aggressive B-cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT03837873 Org: User:
Start: 01/21/19 End: 09/01/24 Due: 09/01/25

Herombopag Added to Cyclosporine in Non Severe Aplastic Anemia

Phase: N/A Priority: Normal
NCT ID: NCT05660785 Org: User:
Start: 12/01/22 End: 01/28/25 Due: 01/28/26

A Prospective, One-arm and Open Clinical Study of Zanubrutinib in the Treatment of Immune Thrombocytopenia

Phase: N/A Priority: Normal
NCT ID: NCT05214391 Org: User:
Start: 02/15/22 End: 12/31/25 Due: 12/31/26

The Mutation Profile and Prognosis in AML With IDH1/2 Mutation

Phase: N/A Priority: Normal
NCT ID: NCT07004816 Org: User:
Start: 12/21/17 End: 03/24/20 Due: 03/24/21